Charlotte Doublet
YOU?
Author Swipe
View article: Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools
Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools Open
Predicting therapeutic failure in patients with chronic phase-chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKI) remains a major challenge for personalized care management. The Sokal and EUTOS long-term surviva…
View article: Nilotinib Versus Nilotinib Combined to Pegylated Interferon-Alpha2a as First-Line Therapy in Chronic Phase Chronic Myeloid Leukaemia. Final Results of the National Academic Phase Iii Petals Trial
Nilotinib Versus Nilotinib Combined to Pegylated Interferon-Alpha2a as First-Line Therapy in Chronic Phase Chronic Myeloid Leukaemia. Final Results of the National Academic Phase Iii Petals Trial Open
View article: Data from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Data from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Purpose:To assess the impact of PHF6 alterations on clinical outcome and therapeutical actionability in T-cell acute lymphoblastic leukemia (T-ALL).Experimental Design:We described PHF6 alterations in an adult cohort of T-ALL from the Fren…
View article: Supplementary Table S2 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Table S2 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Bivalent genes hypermethylated in PHF6 altered T-ALL and targeted by PHF6
View article: Supplementary Table S2 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Table S2 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Bivalent genes hypermethylated in PHF6 altered T-ALL and targeted by PHF6
View article: Supplementary Table S2 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Table S2 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Bivalent genes hypermethylated in PHF6 altered T-ALL and targeted by PHF6
View article: Supplementary Table S3 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Table S3 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Patient cohort used for in vitro drug sensitivity assay.
View article: Supplementary Table S1 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Table S1 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
PHF6 variant allelic frequencies of the additional 37 non protocolar paired diagnosis/relapsed PHF6ALT patients.
View article: Supplementary Table S3 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Table S3 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Patient cohort used for in vitro drug sensitivity assay.
View article: Supplementary Table S3 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Table S3 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Patient cohort used for in vitro drug sensitivity assay.
View article: Supplementary Figure S1 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Figure S1 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Supplementary Figure 1 (A) Circos plot representing mutations co-occurrences in PHF6WT (left) and PHF6ALT T-ALL (right). (B) Variant allele frequencies (VAF) of mutations at diagnosis and relapse. Genes are ordered by decreasing VAF at dia…
View article: Supplementary Figure S2 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Figure S2 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Supplementary Figure 2 (A) Bar graphs showing the significant association between PHF6 status and methylation clusters previously described by our team (1). (B) Kaplan-Meier curve of overall survival between PHF6ALT and PHF6WT patients wit…
View article: Supplementary Table S1 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Table S1 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
PHF6 variant allelic frequencies of the additional 37 non protocolar paired diagnosis/relapsed PHF6ALT patients.
View article: Supplementary Table S2 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Table S2 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Bivalent genes hypermethylated in PHF6 altered T-ALL and targeted by PHF6
View article: Supplementary Table S3 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Table S3 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Patient cohort used for in vitro drug sensitivity assay.
View article: Supplementary Figure S2 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Figure S2 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Supplementary Figure 2 (A) Bar graphs showing the significant association between PHF6 status and methylation clusters previously described by our team (1). (B) Kaplan-Meier curve of overall survival between PHF6ALT and PHF6WT patients wit…
View article: Data from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Data from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Purpose:To assess the impact of PHF6 alterations on clinical outcome and therapeutical actionability in T-cell acute lymphoblastic leukemia (T-ALL).Experimental Design:We described PHF6 alterations in an adult cohort of T-ALL from the Fren…
View article: Supplementary Figure S1 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Figure S1 from <i>PHF6</i>-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Supplementary Figure 1 (A) Circos plot representing mutations co-occurrences in PHF6WT (left) and PHF6ALT T-ALL (right). (B) Variant allele frequencies (VAF) of mutations at diagnosis and relapse. Genes are ordered by decreasing VAF at dia…
View article: <i>PHF6</i> -altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
<i>PHF6</i> -altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax Open
Purpose: To assess the impact of PHF6 alterations on clinical outcome and therapeutical actionability in T-cell acute lymphoblastic leukemia (T-ALL). Experimental Design: We described PHF6 alterations in an adult cohort of T-ALL from the F…